

AGC Acquires a Leading German Biopharmaceutical CMO

Tokyo, September 6, 2016—AGC Asahi Glass (AGC), a world-leading manufacturer of glass, chemicals and high-tech materials, announces that it has acquired all of the shares of Biomeva GmbH (Biomeva) from Biomeva Holding GmbH. Biomeva is one of the leading biopharmaceutical contract manufacturing organizations (CMO) in Europe. With Biomeva now a part of the AGC Group, AGC's Life Science Business will be offering wider geographic coverage and a wider range of capacities.

Based in the Bio Cluster City of Heidelberg, Germany, Biomeva has almost 25 years of experience in providing contract development and manufacturing services using microbial expression technology to European and other International customers. Biomeva's services include process development for highly efficient therapeutic protein expression, cGMP compliant fermentation, purification and bulk filling, as well as analytical testing and cell banking.

Dr. Thomas Pultar, CEO of Biomeva says "By combining Biomeva's capabilities and AGC's large scale manufacturing capacities we will generate a new and strong international microbial CMO, offering the complete services from process development to large scale market supply. To me, this is a perfect synergy between Biomeva's strength in clinical manufacturing and AGC's expertise and capacity for commercial production. I look forward to continuing my role as CEO of Biomeva under this new ownership."

Under the management policy *AGC plus*, the AGC Group has designated Life Science Business as one of its strategic areas. The synergy generated through the business integration of AGC and Biomeva being an important addition, the AGC Group is dedicated to speeding up and expanding its biopharmaceutical contract services business.

Profile of Biomeva GmbH

Company:	Biomeva GmbH
Representative:	Dr. Thomas Pultar
Location:	Heidelberg, Germany
Shareholders:	AGC 100%
Established:	1983
Business Description:	Contract development and manufacturing services using microorganisms for biologic and therapeutic proteins.

<Media inquiries>

Junichi Kobayashi, General Manager, Corporate Communications & Investor Relations Office
AGC Asahi Glass

(Contact: Tomoko Komazaki; Tel: +81-3-3218-5603; E-mail: info-pr@agc.com)

<Reference>

About Biomeva GmbH

Biomeva GmbH, a reliable and experienced contract manufacturing organization (CMO) in the biopharmaceutical industry, is dedicated to meeting the manufacturing needs for the production of microbially expressed protein products. Since 1993, Biomeva has been producing more than 450 batches of cGMP-compliant material for pharmaceutical and biotech companies worldwide at the 100 L and 1000 L scale. Partners benefit from Biomeva's track-proven operational expertise in the transfer, development, optimization, scale-up and validation of cGMP processes. Biomeva offers comprehensive services around cGMP manufacturing and processing of biopharmaceuticals using microorganisms (E. coli and yeast) including cell banking, process development and process optimization (high cell density fermentation, downstream processing and chromatographic purification).

About the AGC Group

AGC Asahi Glass (or also called AGC, Registered Company name: Asahi Glass Co., Ltd., Headquarters: Tokyo, President & CEO: Takuya Shimamura) is the parent company of the AGC Group, a world-leading glass solution provider and supplier of flat, automotive and display glass, chemicals, ceramics and other high-tech materials and components. Based on more than a century of technical innovation, the AGC Group has developed a wide range of cutting-edge products. The AGC Group employs some 50,000 people worldwide and generates annual sales of approximately 1.3 trillion Japanese yen through business in about 30 countries. For more information, please visit www.agc-group.com.

<Media inquiries>

Junichi Kobayashi, General Manager, Corporate Communications & Investor Relations Office

AGC Asahi Glass

(Contact: Tomoko Komazaki; Tel: +81-3-3218-5603; E-mail: info-pr@agc.com)